• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
Moxifloxacin Free Base

Moxifloxacin Free Base

Product ID M5793
Cas No. 151096-09-2
Purity ≥98%
Product Unit SizeCostQuantityStock
100 mg $195.00 In stock
500 mg $681.00 In stock
1 g $875.00 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Moxifloxacin is a fluoroquinolone antibiotic commonly used to treat ocular infections such as bacterial conjunctivitis as well as sinus and lung infections such as pneumonia. Moxifloxacin displays antibacterial efficacy against both gram negative and gram positive bacteria, preventing DNA synthesis in bacterial pathogens by inhibiting topoisomerase IV and bacterial DNA gyrase. This compound is currently being examined as a conjunctive therapy with anticancer agents against several forms of cancer due to its topoisomerase II inhibition. Combining moxifloxacin with anticancer agents yields a cytotoxic drug sparing effect due to the synergism of the mechanisms of action between moxifloxacin and the anticancer drugs.

Product Info

Cas No.

151096-09-2

Purity

≥98%

Formula

C21H24FN3O4

Formula Wt.

401.43

IUPAC Name

7-[(4aS,7aS)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3, 4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3- carboxylic acid

Solubility

Water: 1.5mg/mL Ethanol: 5mg/mL DMSO: 15mg/mL

Appearance

Yellow Solid

Shipping and Storage

Store Temp

4°C

Ship Temp

Ambient

Downloads

MSDS

M5793 MSDS PDF

Info Sheet

M5793 Info Sheet PDF

References

Wohlkonig A, Chan PF, Fosberry AP, et al. Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance. Nat Struct Mol Biol. 2010 Sep;17(9):1152-3. PMID: 20802486.

Reuveni D, Halperin D, Shalit I, et al. Moxifloxacin enhances etoposide-induced cytotoxic, apoptotic and anti-topoisomerase II effects in a human colon carcinoma cell line. Int J Oncol. 2010 Aug;37(2):463-71. PMID: 20596674.

Reuveni D, Halperin D, Fabian I, et al. Moxifloxacin increases anti-tumor and anti-angiogenic activity of irinotecan in human xenograft tumors. Biochem Pharmacol. 2010 Apr 15;79(8):1100-7. PMID: 20025849.

Laponogov I, Sohi MK, Veselkov DA, et al. Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases. Nat Struct Mol Biol. 2009 Jun;16(6):667-9. PMID: 19448616.

Stroman DW, Dajcs JJ, Cupp GA, et al. In vitro and in vivo potency of moxifloxacin and moxifloxacin ophthalmic solution 0.5%, a new topical fluoroquinolone. Surv Ophthalmol. 2005 Nov;50 Suppl 1:S16-31. PMID: 16257308.

Aldred KJ, McPherson SA, Wang P, et al. Drug interactions with Bacillus anthracis topoisomerase IV: biochemical basis for quinolone action and resistance. Biochemistry. 2012 Jan 10;51(1):370-381. PMID: 22126453.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • G0000

    G250.A2 Peptide

    Peptide, carbonic anhydrase G250 epitope.

    ≥95%
  • I7155

    Isoindigo

    Potential AhR binding agent.

    ≥98%
  • C3260

    Ciprofibrate

    Fibrate; PPARα agonist.

    ≥98%
  • D0005

    Dabrafenib Mesylate

    B-Raf and c-Raf inhibitor.

    ≥98%
  • C0172

    Carbimazole

    Methimazole prodrug; thyroid peroxidase inhibit...

    ≥98%
  • K977545

    Kynurenic acid

    Endogenous NMDA receptor antagonist.

    ≥99%
  • I5034

    Imiquimod

    Imidazoquinoline nucleoside analog; TLR-7/8 ago...

    ≥99.5%
  • C3262

    Ciprofloxacin

    Fluoroquinolone; topoisomerase IV and bacterial...

    ≥98%
  • T3584

    Tivantinib

    MET and GSK-3α/β inhibitor.

    ≥98%
  • U7354

    Usnic Acid

    Dibenzofuran produced by lichens.

    ≥98%
  • R3205

    Ribavirin

    Purine nucleoside analog; DNA chain terminator....

    ≥98%
  • P2510

    4-Phenylbutylisothiocyanate

    Synthetic ITC.

    ≥98%
  • B5753

    Bongkrekic Acid

    Respiratory toxin, mitochondrial permeability t...

    ≥95%
  • H1662

    HER2/neu (654-662) GP2

    Peptide fragment of HER2/neu/erbB2 receptor.

    ≥95%
  • V0146

    Valsartan

    AT1 inhibitor.

    ≥98%
  • Z161025

    β-Zearalenol

    Mycotoxin that has structural similarity to est...

    ≥98%
  • R2812

    Recombinant HIV-1 gp-120

    Recombinant HIV glycoprotein antigen fragment.<...

    ≥95%
  • T1672

    Terbinafine Hydrochloride

    Allylamine; squalene oxidase and KSR1 inhibitor...

    ≥98%
  • R0253

    Ranitidine Hydrochloride

    Histamine H2 inverse agonist.

    ≥98%
  • T1014

    7-TES-Paclitaxel

    Synthesis impurity

    ≥95%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2026 LKT Laboratories, All Rights Reserved - Products for research use only